Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024
Dry AMD Symposium 2
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more